MD3522880T2 - Metode de tratare a leziunilor renale acute - Google Patents

Metode de tratare a leziunilor renale acute Download PDF

Info

Publication number
MD3522880T2
MD3522880T2 MDE20190903T MDE20190903T MD3522880T2 MD 3522880 T2 MD3522880 T2 MD 3522880T2 MD E20190903 T MDE20190903 T MD E20190903T MD E20190903 T MDE20190903 T MD E20190903T MD 3522880 T2 MD3522880 T2 MD 3522880T2
Authority
MD
Moldova
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
patient
use according
Prior art date
Application number
MDE20190903T
Other languages
English (en)
Romanian (ro)
Inventor
Bharat Lagu
Michael Patane
Effie Tozzo
Scott Trzaska
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MD3522880T2 publication Critical patent/MD3522880T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
MDE20190903T 2016-10-05 2017-10-05 Metode de tratare a leziunilor renale acute MD3522880T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
MD3522880T2 true MD3522880T2 (ro) 2021-03-31

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190903T MD3522880T2 (ro) 2016-10-05 2017-10-05 Metode de tratare a leziunilor renale acute

Country Status (33)

Country Link
US (1) US20210283116A1 (https=)
EP (1) EP3522880B1 (https=)
JP (1) JP7065839B2 (https=)
KR (1) KR20190062502A (https=)
CN (1) CN109789117B (https=)
AU (1) AU2017340760B2 (https=)
BR (1) BR112019005539A2 (https=)
CA (1) CA3036723A1 (https=)
CO (1) CO2019004561A2 (https=)
CY (1) CY1124759T1 (https=)
DK (1) DK3522880T3 (https=)
ES (1) ES2859487T3 (https=)
HR (1) HRP20210294T1 (https=)
HU (1) HUE053557T2 (https=)
IL (1) IL265749A (https=)
JO (1) JOP20190056B1 (https=)
LT (1) LT3522880T (https=)
MA (1) MA46459B1 (https=)
MD (1) MD3522880T2 (https=)
MX (1) MX387518B (https=)
MY (1) MY192385A (https=)
PH (1) PH12019500725A1 (https=)
PL (1) PL3522880T3 (https=)
PT (1) PT3522880T (https=)
RS (1) RS61573B1 (https=)
RU (1) RU2753607C2 (https=)
SG (1) SG11201901925RA (https=)
SI (1) SI3522880T1 (https=)
SM (1) SMT202100111T1 (https=)
TW (1) TWI778982B (https=)
UA (1) UA124019C2 (https=)
WO (1) WO2018067857A1 (https=)
ZA (1) ZA201901743B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037371B1 (ru) 2015-10-07 2021-03-19 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
US11358954B2 (en) * 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
ES2887008T3 (es) 2016-10-05 2021-12-21 Mitobridge Inc Formas cristalinas y de sal de compuestos agonistas del PPAR
US20220323416A1 (en) 2019-07-19 2022-10-13 Vifor (International) Ag Ferroportin-Inhibitors For The Use In The Prevention And Treatment Of Kidney Injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
MX2023010537A (es) * 2021-03-08 2023-11-28 Abionyx Pharma Sa Compuestos útiles para tratar enfermedades del hígado.
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028500D1 (de) 2003-09-19 2010-09-16 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
EP2981522A4 (en) * 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
EP2862574A1 (en) 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
US10300108B2 (en) * 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20170305894A1 (en) * 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
EA037371B1 (ru) * 2015-10-07 2021-03-19 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения

Also Published As

Publication number Publication date
UA124019C2 (uk) 2021-07-07
JOP20190056B1 (ar) 2022-03-15
TWI778982B (zh) 2022-10-01
HRP20210294T1 (hr) 2021-04-16
US20210283116A1 (en) 2021-09-16
BR112019005539A2 (pt) 2019-06-18
MY192385A (en) 2022-08-18
MA46459A (fr) 2019-08-14
SI3522880T1 (sl) 2021-07-30
RU2019111421A3 (https=) 2021-02-05
TW201815391A (zh) 2018-05-01
RS61573B1 (sr) 2021-04-29
ZA201901743B (en) 2022-04-28
AU2017340760A1 (en) 2019-03-21
MA46459B1 (fr) 2021-03-31
KR20190062502A (ko) 2019-06-05
CO2019004561A2 (es) 2019-07-31
LT3522880T (lt) 2021-03-25
CN109789117A (zh) 2019-05-21
IL265749A (en) 2019-06-30
AU2017340760B2 (en) 2023-07-27
MX2019003949A (es) 2019-06-10
DK3522880T3 (en) 2021-01-18
CN109789117B (zh) 2022-08-23
RU2019111421A (ru) 2020-11-06
PT3522880T (pt) 2021-02-22
JP7065839B2 (ja) 2022-05-12
PL3522880T3 (pl) 2021-08-23
ES2859487T3 (es) 2021-10-04
RU2753607C2 (ru) 2021-08-18
HUE053557T2 (hu) 2021-07-28
EP3522880B1 (en) 2020-12-02
JP2019533660A (ja) 2019-11-21
WO2018067857A1 (en) 2018-04-12
JOP20190056A1 (ar) 2019-03-24
SMT202100111T1 (it) 2021-05-07
EP3522880A1 (en) 2019-08-14
MX387518B (es) 2025-03-18
CY1124759T1 (el) 2022-07-22
CA3036723A1 (en) 2018-04-12
SG11201901925RA (en) 2019-04-29
PH12019500725A1 (en) 2019-08-05

Similar Documents

Publication Publication Date Title
MD3522880T2 (ro) Metode de tratare a leziunilor renale acute
JP6938705B2 (ja) 多発性嚢胞腎の予防及び/又は治療薬
IL211429A (en) HISTORY 1 - Naphthalene triazole and a pharmaceutical composition containing them
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CA3095164A1 (en) Calpain modulators and therapeutic uses thereof
CN114085235B (zh) 杂环衍生物化合物的制备方法、包含所述化合物的组合物及所述化合物的水合物
HUT76542A (en) Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
IL298833A (en) Methods for treating or preventing chronic kidney disease
AU2011252151A1 (en) Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
HK40008682B (en) Methods of treating acute kidney injury
HK40008682A (en) Methods of treating acute kidney injury
CZ182895A3 (en) Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide per se and for treating diseases, and pharmaceutical composition based thereon
JP6861726B2 (ja) 糖尿病性腎症の治療薬または予防薬
US20090281083A1 (en) Combination Product
WO2023225300A2 (en) Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto
Iacovone Design and synthesis of Human Neutrophil Elastase (HNE) inhibitors
JP2000086508A (ja) ヒスタミン遊離抑制剤
JPS634807B2 (https=)
WO2013075624A1 (zh) 甘氨酸重摄取抑制剂及其应用
HK1179890A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction